The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Exploring the combination of brentuximab vedotin & nivolumab in older patients with Hodgkin lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, shares insights into a study that explored the combination of brentuximab vedotin and nivolumab for the treatment of older patients with Hodgkin lymphoma. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I mean the obvious thing is to say if you’ve got two new agents, both of which are highly effective, if you put them together, could that be sufficient, and could you just leave chemotherapy out entirely? So we actually explored that in a combination. Bruce Cheson led that study, and we were part of it. Brentuximab vedotin plus nivolumab alone as two new drugs together in elderly patients...
I mean the obvious thing is to say if you’ve got two new agents, both of which are highly effective, if you put them together, could that be sufficient, and could you just leave chemotherapy out entirely? So we actually explored that in a combination. Bruce Cheson led that study, and we were part of it. Brentuximab vedotin plus nivolumab alone as two new drugs together in elderly patients. I think things we learned from that was that if you just give a short, simplified kind of regimen where you just give it for six to eight months and then stop, you get good response rates, but the durability is not as good as what we would wish. It really seems that when you’re using these new agents together, but not without any chemotherapy, you’re definitely going to need to give it for a longer period of time. We do see a population of patients, sort of long-term, that are doing very well, even just with those two agents. So I think the next set of studies are going to need to look at how you can make that population that does well greater, probably with a longer course of treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
